Isofol Medical Q3: Continues according to plan

Research Note

2019-11-13

11:38

Isofol continues to ramp up patient recruitment and reiterates the plans to expand the AGENT trial to new markets. Further, the company reports that they are carrying out activities to increase the awareness of arfolitixorin in the scientific community and among potential partners. In conjunction with the report, it was announced that Anders Rabbe will step down of Isofol and that the chairman of the board, Dr Jarl Ulf Jungnelius, M.D., is appointed as the new CEO.

AN

Arvid Necander

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.